Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $194.19M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.43M
Average 0.36M
Returns on capital
Entrada Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.0%
avg -0.3%
ROIC
-43.7%
avg -32.9%
ROA
-38.1%
avg -24.0%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Dipal Doshi | Chief Executive Officer & Director | USD 998.25K | 50 | 517.29K | 1.33% |
Natarajan Sethuraman | President of Research & Development | USD 768K | 64 | 214.24K | 0.55% |
Nathan J. Dowden | President & Chief Operating Officer | USD 737.18K | 55 | 196.06K | 0.51% |
Kerry Robert | Senior Vice President of People | — | — | — | — |
Jared Cohen | General Counsel | — | — | — | — |
Kevin Healy | Senior Vice President of Regulatory Affairs | — | — | — | — |
Kory James Wentworth | Chief Financial Officer & Treasurer | — | 47 | 117.28K | 0.30% |
Karla MacDonald | Chief Corporate Affairs Officer | — | — | — | — |
Linea Aspesi | Chief People Officer | — | 56 | — | — |
Sandeep Basnet | Head of Information Technology | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$291,162.12
Sells
42
$11.58M
Net Transaction Value
−$11.29M
Net selling
Most Active
MPM BIOVENTURES 2018, L.P.
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 9, 26Sep 9, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $205.6K$205,607.81 |
| Sep 9, 26Sep 9, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $205.6K$205,607.81 |
| Sep 8, 26Sep 8, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $1.4M$1,426,425.00 |
| Sep 8, 26Sep 8, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $1.4M$1,426,425.00 |
| Sep 4, 26Sep 4, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $273.7K$273,735.00 |
| Sep 4, 26Sep 4, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $273.7K$273,735.00 |
| Sep 3, 26Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $231.3K$231,325.71 |
| Sep 3, 26Sep 3, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $231.3K$231,325.71 |
| Sep 2, 26Sep 2, 2026 | MPM BIOVENTURES 2018, L.P. Indirect | Sell | $180.7K$180,691.89 |
| Sep 2, 26Sep 2, 2026 | MPM BioVentures 2014, L.P. Indirect | Sell | $180.7K$180,691.89 |
1–10 of 47
Summary
Insiders reported 5 buys worth $291,162.12 and 42 sells worth $11.58M over the last 12 months. That adds up to net selling of $11.29M. MPM BIOVENTURES 2018, L.P. was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +38.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +38.0% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Entrada Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TRDA's management, answered from reported figures.
Who manages TRDA?
Entrada Therapeutics, Inc. (TRDA) lists 10 active executives. The top listed executive is Kerry Robert, Senior Vice President of People.
Are TRDA insiders buying or selling?
Recent insider activity shows net selling of $7.66M.
Continue the stock analysis
Jump to another research area for this company.